ArticleAnnals of medicine and surgery (2012)2026
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches. This systematic review and meta-analysis evaluated their efficacy and safety in adults with overweight or obesity. Methods: Four databases were searched from inception to March 2026. Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo. Outcomes included percentage and absolute body weight change, waist circumference, blood pressure, HbA1c, and adverse events. Data were pooled using random-effects models in RevMan, with results expressed as mean differences (MD) or risk ratios (RR) with 95% confidence intervals. Results: Four RCTs encompassing 5425 participants were included. Cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg) and blood pressure, without meaningful HbA1c improvement. CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c. Both treatments showed modest but statistically significant increases in adverse events. Substantial heterogeneity was observed across most outcomes. Conclusion: Cagrilintide-based therapies produce clinically meaningful weight loss and cardiometabolic improvements. CagriSema demonstrates additional glycemic benefits over monotherapy. Larger, longer-duration trials are needed to confirm long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.